VEGF (Vascular Endothelial Growth Factor) is a growth factor necessary for the development of vessels in a tumor (among others). The VGX100, developed by Circadian Technologies Limited, which specializes in antibodies directed against VEGF, is an inhibitor of this factor.
The results of the study to be presented soon show that in combination with docetaxel (an antimitotic agent used in chemotherapy) and bevacizumab (Avastin, also antibody against VEGF), this drug offers survival 2.7 times higher in mice bearing prostate tumors the study period, compared to the association without VGX100. An interesting statistic is that the combination of three drugs enabled 40% of the mice finished the study without tumor, against 0% in other cases.
The worldwide turnover of Avastin, owned by Roche, is almost U.S. $ 9 billion, which shows the potential of this new Antibodies: VGX100.
http://www.caducee.net/breves/breve.asp?idb=9582&mots=all
0 comments:
Post a Comment